Literature DB >> 31734756

Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.

Oliver Graupner1, Anne Karge2, Sarah Flechsenhar2, Alina Seiler2, Bernhard Haller3, Javier U Ortiz2, Silvia M Lobmaier2, Roland Axt-Fliedner4, Christian Enzensberger4, Kathrin Abel2, Bettina Kuschel2.   

Abstract

PURPOSE: The sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio and uterine artery Doppler have shown to be helpful in the diagnosis of pre-eclampsia (PE). The predictive value of the cerebroplacental ratio (CPR) regarding adverse perinatal outcome (APO) in low-risk pregnancies is intensively discussed. We evaluated the extent to which sFlt-1/PlGF ratio and feto-maternal Doppler may be useful in predicting APO in singleton pregnancies complicated by late-onset PE and/or HELLP syndrome.
METHODS: This is a retrospective study from 2010 to 2018 consisting of singleton pregnancies with confirmed diagnosis of late-onset (lo ≥ 34 weeks) PE/HELLP syndrome in which sFlt-1/PlGF ratio and feto-maternal Doppler (mUtA-PI: mean uterine artery pulsatility index and CPR) were determined. The ability of sFlt-1/PlGF ratio, mUtA-PI, CPR and their combination to predict APO or SGA was evaluated using receiver operating characteristic (ROC) curves.
RESULTS: 67 patients were included in the final analysis. Of these, sFlt-1/PlGF was > 110 (defining angiogenic lo PE) in 40.3% (27/67), mUtA-PI was above the 95th centile in 34.3% (23/67) patients and CPR was lower than the 5th centile in 10.4% (7/67). Abnormal sFlt-1/PlGF and mUtA-PI as well as CPR were associated with a lower birth weight (BW). Late-preterm birth (< 37 weeks) as well as postnatal diagnosis of small for gestational age (SGA: BW < 3rd centile) was significantly more often in angiogenic lo PE cases. Neither sFlt-1/PIGF nor CPR or mUtA-PI were APO predictors. Only for sFlt-1/PlGF, ROC analysis revealed a significant predictive value for postnatal SGA (AUC = 0.856, p = 0.001, 95% CI 0.75-0.97). There was no statistical added value of combined SGA predictors as compared to sFlt-1/PlGF alone.
CONCLUSIONS: In patients with lo PE, adding sFlt-1/PlGF ratio to routine antepartum fetal surveillance may be useful to identify cases of postnatal SGA. However, further prospective studies are warranted to define the role of feto-maternal Doppler and sFlt-1/PlGF ratio as outcome predictors.

Entities:  

Keywords:  (anti-) Angiogenic factors; Cerebroplacental ratio; Placental growth factor; Preeclampsia; Soluble fms-like tyrosine kinase 1; Uterine artery Doppler

Year:  2019        PMID: 31734756     DOI: 10.1007/s00404-019-05365-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

1.  Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome.

Authors:  Shuangyan Yang; Junfeng Zhang; Dan Chen; Jie Ding; Yanhong Zhang; Lili Song
Journal:  Drugs R D       Date:  2022-09-22

2.  Performance of sFlt-1/PIGF Ratio for the Prediction of Perinatal Outcome in Obese Pre-Eclamptic Women.

Authors:  Anne Karge; Linus Desing; Bernhard Haller; Javier U Ortiz; Silvia M Lobmaier; Bettina Kuschel; Oliver Graupner
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

3.  Value of Cerebroplacental Ratio and Uterine Artery Doppler as Predictors of Adverse Perinatal Outcome in Very Small for Gestational Age at Term Fetuses.

Authors:  Anne Karge; Silvia M Lobmaier; Bernhard Haller; Bettina Kuschel; Javier U Ortiz
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

4.  The Impact of Increased Maternal sFlt-1/PlGF Ratio on Motor Outcome of Preterm Infants.

Authors:  Lisa Middendorf; Alexandra Gellhaus; Antonella Iannaccone; Angela Köninger; Anne-Kathrin Dathe; Ivo Bendix; Beatrix Reisch; Ursula Felderhoff-Mueser; Britta Huening
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.